23andMe

23andMe is a leading personal genetics company that provides DNA-based insights into health and ancestry. While not directly mentioned in the provided snippets, the company's core business of genetic analysis is highly relevant to recent discussions surrounding the efficacy of obesity medications like Ozempic and Mounjaro. These articles highlight that individual genetic makeup plays a significant role in how effectively these GLP-1 receptor agonist drugs work for weight loss. Factors such as genetic variants, age, and sex can influence a person's response to these revolutionary treatments, which mimic natural satiety hormones. Therefore, 23andMe's genetic testing capabilities are indirectly newsworthy as they offer a potential avenue for understanding and perhaps personalizing the use of these powerful new obesity drugs, explaining why they don't work uniformly across all patients. The company's technology underpins the growing understanding of pharmacogenomics, the study of how genes affect a person's response to drugs.